FinVector is a contract development and manufacturing organization within the R&D and cGMP manufacturing of Viral-Based Gene Therapy products. FinVector is authorized under EMA for the production of gene therapy products for clinical and commercial supply. The company offers services across a wide range of viral-based product types, including Adenoviral, AAV, and Lentiviral-based vectors.
